News & Publications

Recent Press Releases

cyteir 2020-07-07T13:09:13+00:00 July 7th, 2020|

Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer [...]

cyteir 2019-10-14T15:57:19+00:00 October 15th, 2019|

Cyteir Therapeutics Secures Additional $40.2 Million in its Series B Financing and Doses [...]

cyteir 2019-04-01T14:12:34+00:00 March 31st, 2019|

Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas [...]

cyteir 2018-03-08T12:03:05+00:00 March 8th, 2018|

Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies [...]

Ratiu JJ, Racine JJ, Hasham MG, Wang, Q, Branca J, Chapman HD, Zhu J, Donghia N, Philip V, Schott WH, Wasserfall C, Atkinson MA, Mills KD, Leeth CM, Serreze DV. Genetic and Small Molecule Disruption of the AID/RAD51 Axis Similarly Ptotects Nonobese Diabetic Mice from Type 1 Diabetes through Expansion of Regulatory B Lymphocytes. (2017) Journal of Immunology. June; 198(11): 4255-4267. Doi: 10.4049/jimmunol.1700024. Epub 2017 May 1. PMID: 28461573
Lamont KR, Hasham MG, Donghia NM, Branca J, Chavaree M, Chase B, Breggia A, Hedlund J, Emery I, Cavallo F, Jasin M, Ruter J, Mills KD. Attenuating homologous recombination stimulate an AID-induced antileukemic effect. (2013) Journal of Experimental Medicine. May; 210(5):1021-33.
Hasham MG, Donghia NM, Coffey E, Maynard J, Snow KJ, Ames J, Wilpan RY, He Y, King BL, Mills KD. Widespread genomic breaks generated by activation-induced cytidine deaminase are prevented by homologous recombination. (2010) Nature Immunology. September; 11(9): 820-826.